Prevalence and predictors of anti-SARS-CoV-2 serology in a highly vulnerable population of Rio de Janeiro: A population-based serosurvey

作者：L. Coelho, P. Luz, D. C. Pires, E. Jalil, H. Perazzo, T. Torres, S. W. Cardoso, E. Peixoto, Sandro C Nazer, E. Massad, M. F. Silveira, Fernando C. Barros, Ana Teresa Ribeiro Vasconcelos, C. A. Costa, R. Amancio, D. Villela, T. Pereira, G. Goedert, C. V. Santos, N. Rodrigues, B. Grinsztejn, V. Veloso, C. Struchiner · 发表于：The Lancet Regional Health - Americas · 年份：2022 · DOI：10.1016/j.lana.2022.100338 · 被引用次数：20 · 研究领域：Medicine

Summary Background COVID-19 serosurveys allow for the monitoring of the level of SARS-CoV-2 transmission and support data-driven decisions. We estimated the seroprevalence of anti-SARS-CoV-2 antibodies in a large favela complex in Rio de Janeiro, Brazil. Methods A population-based panel study was conducted in Complexo de Manguinhos (16 favelas) with a probabilistic sampling of participants aged ≥1 year who were randomly selected from a census of individuals registered in primary health care clinics that serve the area. Participants answered a structured interview and provided blood samples for serology. Multilevel regression models (with random intercepts to account for participants’ favela of residence) were used to assess factors associated with having anti-S IgG antibodies. Secondary analyses estimated seroprevalence using an additional anti-N IgG assay. Findings 4,033 participants were included (from Sep/2020 to Feb/2021, 22 epidemic weeks), the median age was 39·8 years (IQR:21·8-57·7), 61% were female, 41% were mixed-race (Pardo) and 23% Black. Overall prevalence was 49·0% (95%CI:46·8%-51·2%) which varied across favelas (from 68·3% to 31·4%). Lower prevalence estimates were found when using the anti-N IgG assay. Odds of having anti-S IgG antibodies were highest for young adults, and those reporting larger household size, poor adherence to social distancing and use of public transportation. Interpretation We found a significantly higher prevalence of anti-S IgG antibodie...